Observational studyMovement disorders clinical practice2025
Clinical Impact of Switching from Subcutaneous Apomorphine to Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: A Real-World Observational Study (FOSAPO).
Observational study in Movement disorders clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Real-world experience with foslevodopa/foscarbidopa in Germany: therapeutic insights and lessons learned.Neurological research and practice · 2026Review
- Review
- Real-world outcomes and early discontinuation of foslevodopa/foscarbidopa in Parkinson's disease.Journal of neurology · 2026Article
- A narrative review of clinical and non-clinical determinants of health-related quality of life in advanced Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Real-world implementation of continuous subcutaneous foslevodopa/foscarbidopa in advanced Parkinson's disease: first clinical experience from the Middle East.Therapeutic advances in neurological disorders · 2026Article
- Reply: "Navigating the Neuropsychiatric Risks of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease".Movement disorders clinical practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContinuous subcutaneous foslevodopa/foscarbidopa (CSFLI) is emerging as a new treatment for advanced Parkinson's disease (APD), but its efficacy and safety as a second-line infusion therapy in patients previously treated with apomorphine remain to be clarified.
objectivesThe aim of this study was to evaluate the short-term clinical impact of switching from continuous subcutaneous apomorphine infusion (CSAI) to CSFLI in a real-world cohort.
methodsWe conducted a retrospective observational study including 14 patients with APD who transitioned from CSAI to CSFLI. Clinical assessments were performed at baseline (M0) and 3 months after the switch (M3).
resultsAt M3, motor complications (Movement Disorder Society-the Unified Parkinson's Disease Rating Scale [MDS-UPDRS Part IV]) were significantly reduced, with improvements in functional scores (Part II), quality of life (Parkinson's Disease Questionnaire-8 [PDQ-8]), clinical global impression of severity (CGI-S), and neuropsychiatric inventory (NPI). No patient discontinued treatment. Two patients developed de novo apathy.
conclusionSwitching from CSAI to CSFLI is feasible, effective, and well tolerated. Behavioral changes observed in two cases underline the need for clinical awareness when treating patients with subtle cognitive vulnerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.